Immutep (IMMP) Competitors $1.92 -0.05 (-2.54%) Closing price 02/21/2025 04:00 PM EasternExtended Trading$1.98 +0.06 (+3.07%) As of 02/21/2025 07:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends IMMP vs. GYRE, MRVI, PAHC, ELVN, COLL, ZYME, NTLA, COGT, PHVS, and PSTXShould you be buying Immutep stock or one of its competitors? The main competitors of Immutep include Gyre Therapeutics (GYRE), Maravai LifeSciences (MRVI), Phibro Animal Health (PAHC), Enliven Therapeutics (ELVN), Collegium Pharmaceutical (COLL), Zymeworks (ZYME), Intellia Therapeutics (NTLA), Cogent Biosciences (COGT), Pharvaris (PHVS), and Poseida Therapeutics (PSTX). These companies are all part of the "pharmaceutical products" industry. Immutep vs. Gyre Therapeutics Maravai LifeSciences Phibro Animal Health Enliven Therapeutics Collegium Pharmaceutical Zymeworks Intellia Therapeutics Cogent Biosciences Pharvaris Poseida Therapeutics Gyre Therapeutics (NASDAQ:GYRE) and Immutep (NASDAQ:IMMP) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, valuation, earnings, dividends, institutional ownership, risk, media sentiment, community ranking and analyst recommendations. Does the media prefer GYRE or IMMP? In the previous week, Gyre Therapeutics had 1 more articles in the media than Immutep. MarketBeat recorded 1 mentions for Gyre Therapeutics and 0 mentions for Immutep. Gyre Therapeutics' average media sentiment score of 0.98 beat Immutep's score of 0.00 indicating that Gyre Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Gyre Therapeutics Positive Immutep Neutral Do insiders and institutionals hold more shares of GYRE or IMMP? 24.0% of Gyre Therapeutics shares are held by institutional investors. Comparatively, 2.3% of Immutep shares are held by institutional investors. 19.5% of Gyre Therapeutics shares are held by company insiders. Comparatively, 3.1% of Immutep shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Do analysts rate GYRE or IMMP? Immutep has a consensus price target of $8.50, indicating a potential upside of 342.71%. Given Immutep's stronger consensus rating and higher possible upside, analysts clearly believe Immutep is more favorable than Gyre Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Gyre Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Immutep 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more risk & volatility, GYRE or IMMP? Gyre Therapeutics has a beta of 1.97, suggesting that its share price is 97% more volatile than the S&P 500. Comparatively, Immutep has a beta of 2.21, suggesting that its share price is 121% more volatile than the S&P 500. Which has better valuation and earnings, GYRE or IMMP? Immutep has lower revenue, but higher earnings than Gyre Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGyre Therapeutics$113.45M9.51-$92.93MN/AN/AImmutep$5.14M54.37-$28.01MN/AN/A Is GYRE or IMMP more profitable? Immutep has a net margin of 0.00% compared to Gyre Therapeutics' net margin of -84.57%. Immutep's return on equity of 0.00% beat Gyre Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Gyre Therapeutics-84.57% -118.43% -71.97% Immutep N/A N/A N/A Does the MarketBeat Community believe in GYRE or IMMP? Immutep received 312 more outperform votes than Gyre Therapeutics when rated by MarketBeat users. CompanyUnderperformOutperformGyre TherapeuticsN/AN/AImmutepOutperform Votes31272.56% Underperform Votes11827.44% SummaryImmutep beats Gyre Therapeutics on 10 of the 15 factors compared between the two stocks. Get Immutep News Delivered to You Automatically Sign up to receive the latest news and ratings for IMMP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IMMP vs. The Competition Export to ExcelMetricImmutepPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$286.75M$7.06B$5.84B$9.14BDividend YieldN/A2.76%4.76%3.85%P/E RatioN/A2.9318.2614.95Price / Sales54.37281.18434.4770.76Price / CashN/A65.9238.4235.17Price / Book1.836.717.644.65Net Income-$28.01M$138.11M$3.18B$245.69M7 Day Performance-2.04%-2.54%-1.95%-2.68%1 Month Performance-2.04%-2.00%-0.23%-2.16%1 Year Performance-15.79%-5.04%16.69%12.90% Immutep Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IMMPImmutep0.9739 of 5 stars$1.92-2.5%$8.50+342.7%-13.9%$286.75M$5.14M0.002,021Upcoming EarningsGYREGyre Therapeutics0.2947 of 5 stars$11.91-1.6%N/A-18.3%$1.11B$105.03M0.0040MRVIMaravai LifeSciences4.0154 of 5 stars$4.30-6.1%$10.28+139.1%-21.9%$1.09B$288.95M-2.62610Options VolumeNews CoverageGap UpPAHCPhibro Animal Health4.0924 of 5 stars$26.22+10.7%$21.00-19.9%+79.6%$1.06B$1.11B54.631,940Analyst RevisionHigh Trading VolumeELVNEnliven Therapeutics1.8273 of 5 stars$21.55-2.0%$38.25+77.5%+34.9%$1.05BN/A-11.3450COLLCollegium Pharmaceutical3.901 of 5 stars$30.52-1.0%$43.60+42.9%-8.3%$984.27M$566.77M13.16210News CoverageZYMEZymeworks2.1069 of 5 stars$14.19-0.6%$19.17+35.1%+22.6%$977.41M$76.01M-9.46460NTLAIntellia Therapeutics4.3943 of 5 stars$9.58-2.1%$48.71+408.4%-54.7%$975.71M$43.09M-1.76600News CoverageGap UpCOGTCogent Biosciences1.5442 of 5 stars$8.76+0.2%$14.33+63.6%-6.5%$967.65MN/A-3.5380PHVSPharvaris2.2253 of 5 stars$17.86-2.4%$40.50+126.8%-40.7%$933.90MN/A-6.3830Positive NewsPSTXPoseida Therapeutics1.1178 of 5 stars$9.50flat$9.50N/A$928.85M$150.86M-15.08260 Related Companies and Tools Related Companies Gyre Therapeutics Alternatives Maravai LifeSciences Alternatives Phibro Animal Health Alternatives Enliven Therapeutics Alternatives Collegium Pharmaceutical Alternatives Zymeworks Alternatives Intellia Therapeutics Alternatives Cogent Biosciences Alternatives Pharvaris Alternatives Poseida Therapeutics Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:IMMP) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredWhy Buffett and 100 members of Congress are Piling into this One InvestmentThis isn't just another investment. It might be the last retirement stock you'll ever need. But this win...Behind the Markets | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredThis Crypto Is Set to Explode in FebruaryIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredMarket down? Do this now.During Trump's first term, his tariffs sent gold prices soaring. Investors who acted early made a fortune. Now...Colonial Metals | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immutep Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Immutep With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
